Industry
Report Finds 340B Hospitals Spend Less on Charity Care Than Non-340B Peers
A new report finds hospitals participating in the 340B drug pricing program spend less on charity care than non-participating hospitals, contrary to the program's intent to support safety-net care. The findings intensify ongoing debate over 340B program integrity and whether participating hospitals deliver commensurate community benefits. Critics argue the program has expanded without corresponding patient benefits, while hospital groups dispute the methodology of such studies. The report has no immediate regulatory implications but may inform future congressional or CMS oversight of 340B hospital eligibility and accountability measures.
Why it mattersThe findings may strengthen momentum for federal or state-level 340B program reforms that could affect Medicaid managed care pharmacy costs and provider network composition, particularly if new accountability requirements lead hospitals to exit the program or restrict contract pharmacy arrangements.